Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Stakeholder Insight: Psoriasis - Biologics are yet to make topical treatments obsolete

Stakeholder Insight: Psoriasis - Biologics are yet to make topical treatments obsolete

Patient perception of disease severity drives treatment-seeking behavior in psoriasis. New therapeutic options targeting specific mechanisms are set to reshape severe psoriasis therapy. However, current biologics have not undermined first-line topical therapy. In addition to efficacy, reimbursement plays a crucial role in physicians' prescribing decisions.

Scope

*Opinion from 180 practicing dermatologists, each treating at least 40 psoriasis patients per month

*Including data from physicians and opinion leaders across the seven major markets of the US, Japan, France, Germany, Spain, Italy and the UK

*Analysis of psoriasis population attributes, physicians' prescribing decisions, therapy outcomes and treatment satisfaction

*Brand analysis of key pharmaceuticals used in psoriasis, including biologics and branded topical formulations

Highlights

The low estimated diagnosis rate of 54% reflects a lack of treatment-seeking by mild sufferers. Despite nearly 10 million diagnosed patients, the market value of psoriasis is constrained by reliance on generic and non-prescription treatments in mild disease.

Biologics' risk-benefit and cost-benefit ratios are coming under review. Humira (adalimumab) and Stelara (ustekinumab) stand to benefit from the withdrawal of Raptiva (efalizumab) from the EU and more stringent labeling in the US. The position of biologics in moderate to severe psoriasis is up for challenge by payers attempting to control costs.

Topical treatments are the foundation of therapy, used alone by at least 82% of mild patients. Phototherapy is a cost-effective treatment option in psoriasis unresponsive to topical therapy. Most physicians surveyed recommend phototherapy to up to 30% of patients, and payers may influence greater use of phototherapy.

Reasons to Purchase

*Understand how patient behavior controls the size of the psoriasis market

*Interpret physicians' priorities in prescribing personalized psoriasis treatment regimens

*Assess the regional dynamics of therapy choice in psoriasis, dictated by product availability, regulation and reimbursement

10-Mar-09 PDF & SlidePack Pages: 185

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions